Greenland Mines Ltd. Common Stock
GRMLStock
$0.25
Market Cap$29.01M
P/E—
Div yield—
Beta1.53
Price Chart
Favorite Metrics
Price vs S&P 500 (4W)-34.42%
VGM Score9.73
Market Capitalization$29.01M
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GRMLGreenland Mines Ltd. Common Stock | — | — | F | $0.25 |
| AMGNAmgen Inc | C | C | C | $358.31 |
| GILDGilead Sciences Inc | C | B | C | $126.05 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.48 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $178.70 |
| BIIBBiogen Inc. Common Stock | B | D | B | $214.25 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $89.12 |
| MRNAModerna, Inc. Common Stock | D | B | B | $66.60 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $167.72 |
| EXELExelixis Inc | C | B | B | $54.36 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $366.58 |
About
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.